Transaction DateRecipientSharesTypePriceValue
10th June 2020Enterprise Associates 12, Limited Partnership New1,482,809Other acquisition or disposition$0.00
9th December 2019Enterprise Associates 12, Limited Partnership New400,000Grant/award etc.$6.25$2,500,000.00
27th November 2019Enterprise Associates 12, Limited Partnership New1,166,755Open or private sale$2.52$2,941,739.38
26th November 2019Enterprise Associates 12, Limited Partnership New117,164Open or private sale$2.45$287,133.81
4th February 2019Geoffrey S. Gilmartin9,189Open or private sale$2.99$27,479.70
4th February 2019Po Shun Lee9,931Open or private sale$2.99$29,699.65
4th February 2019Meenu Chhabra16,478Open or private sale$2.99$49,305.47
4th February 2019Benito Munoz9,514Open or private sale$2.99$28,453.52
1st February 2019Meenu Chhabra46,875Exercise of derivative$0.00
1st February 2019Benito Munoz24,953Exercise of derivative$0.00
Proteostasis Therapeutics
Proteostasis Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases.

Ticker: PTI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1445283
Employees: 44
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags